Jan D’Alvise is a veteran life sciences executive, entrepreneur, and board director with over 30 years of leadership across pharmaceuticals, medical devices, diagnostics, Health IT, and AI. As Co-Founder and Managing Partner of HealthPath Strategies and former CEO of multiple public and private companies, she has raised more than $550 million in capital, led major turnarounds and M&A transactions, and continues to guide healthcare innovators in building scalable, fundable ventures worldwide.

Ruben Argueta, with 25+ years in life sciences, has led Operations, Investor Relations, Communications, and Board Relations for both startups and global public companies. He supported 16X market cap growth through transformative M&A at QuidelOrtho, built its acclaimed Investor Relations function, led Crisis Communications through the pandemic, and most recently served as COO of healthcare AI startup RadioEye.

Reo Carr is the Co-Founder and Chief Technologist of HealthPath Strategies and Founder of the Research Group of Companies (RGOC), with more than 25 years of experience driving commercialization, global expansion, and investment strategy across healthcare and medical innovation. He has led initiatives spanning diagnostics, digital health, and AI-enabled technologies, as well as healthcare information systems, guiding physician-entrepreneurs and healthcare innovators in building scalable, fundable, and market-ready ventures.

Dave Karlander is a biotech executive with 25+ years in diagnostics, pharma, and devices, driving commercialization, market access, and strategic growth. He has led major product launches at Circular Genomics, Biocept, Exact Sciences, and Novartis, and he mentors early-stage biotech companies while advancing innovation in oncology, neurology, and infectious diseases.

Brian is an experienced CFO with over 40 years of experience in finance, strategy, and biotech, holding CPA and CA designations from McGill, and more than 20 years of accounting and audit experience at EY. He has led multimillion-dollar financings, M&A, and turnarounds at firms like Telesta, AIM, and Acasti Pharma, and now advises biotech startups and healthcare innovators on growth and transformation.

Andrew de Guttadauro is a senior biopharmaceutical executive with over 30 years of leadership experience spanning business development, commercialization, and corporate strategy in both domestic and international markets. His expertise lies in building and scaling companies—from multinational biopharma giants to early-stage startups—through high-impact strategic partnerships, licensing agreements, and commercial innovation.